Recent Company News

• 02:15 AM ET Apr 01, 2026
  

  Orion upgraded to buy from accumulate at Inderes (timing uncertain) (€69.70, 0.00)

• 11:30 PM ET Mar 09, 2026
  

  Orion upgraded to buy from hold at Danske Bank (€68.55, 0.00)

• 02:24 AM ET Feb 16, 2026
  

  Celltrion reports new data from post-hoc analysis of LIBERTY studies of subcutaneous infliximab for Crohn's disease and ulcerative colitis; to present the data at ECCO (KRW 238000.0000, 0)

• 08:17 AM ET Feb 12, 2026
  

  Transcript Intelligence: Orion Q4 Earnings Guidance

• 08:16 AM ET Feb 12, 2026
  

  Transcript Intelligence: Orion Q4 Earnings Themes

• 08:16 AM ET Feb 12, 2026
  

  Transcript Intelligence: Orion Q4 Earnings Q&A

• 05:07 AM ET Feb 12, 2026
  

  Orion reports Q4 EPS €1.85 vs FactSet €1.98 [6 est, €1.88-2.12]; hikes divi by ~10% (€70.20, -4.40)

• 04:14 AM ET Feb 12, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (208 total)

• 04:05 AM ET Feb 09, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (137 total)

• 04:04 AM ET Feb 03, 2026
  

  Bayer AG's Nubeqa (darolutamide) receives third approval in China for men with advanced prostate cancer (€45.51, +0.50)